NFE2L2/NRF2 is a transcription factor and master regulator of cellular antioxidant response. 28
Introduction 42
The transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2, hereafter referred to 43 as NRF2) is central to the cellular response to oxidative and electrophilic stress (Itoh et al., 2010; 44 Suzuki and Yamamoto, 2015). When active, NRF2 provides strong cytoprotective functions by 45 upregulating expression of: 1) xenobiotic metabolism enzymes, 2) phase II detoxification 46 enzymes, 3) drug efflux pumps, and 4) the thioredoxin and glutathione antioxidant systems ( Here, we performed a gain-of-function (GOF) screen of human kinases to identify new regulators 72 of NRF2-dependent transcription. We focused on kinases given their exceptional druggability and 73 because a rigorous, comprehensive annotation of the kinome for NRF2 activity is lacking. Our 74 previous phosphoproteomic analysis of KEAP1 and NRF2 shows both proteins are 75 phosphorylated at multiple sites. The majority of these phosphorylation events are not linked to 76 specific kinases and are of unknown functional importance (Tamir et al., 2016) . That said, recent 77 studies have revealed a few kinases that influence NRF2 protein stability, subcellular localization 78 and transcriptional activity. NRF2 is directly phosphorylated by GSK3β, resulting in NRF2 79 ubiquitylation by βTrCP and subsequent proteasomal degradation (Chowdhry et al., 2012; 80
Cuadrado, 2015). PKC and AMPK mediated phosphorylation of NRF2, at S40 and S550, 81 respectively, leads to increased NRF2 stability and signaling (Huang, 2002; Joo et al., 2016) .
82
NRF2 is reported to be a substrate of several MAPKs (e.g. JNK, p38, ERK1/2, ASK1, and TAK1), Phosphorylation of KEAP1 or its interacting partners also induces NRF2 stability and signaling. 91
For example, a recent study reports that phosphorylation of KEAP1 by MST1/2 on 92 T51/S53/S55/S80 reduces NRF2 ubiquitylation (Wang et al., 2019) . Additionally, proteins 93
containing ETGE-like motifs, such as p62/SQSTM1, bind to KEAP1 and stabilize NRF2 upon 94 phosphorylation by upstream kinases (e.g. mTORC1, TAK1) ( NRF2 protein levels in HEK293T cells ( Fig. 2E , compare lanes 5-7 with 1 and 2). To further 162 explore a role for KEAP1 in mediating BRSK2-suppression of NRF2, we tested if BRSK2 over-163 expression could block a constitutively active mutant of NRF2 that does not bind KEAP1 (NRF2 164 ∆ETGE). BRSK2 repressed both wild type NRF2 and NRF2 ∆ETGE ( Fig. 2F) . 165 BRSK1 is a paralog to BRSK2, sharing ~68% amino acid sequence similarity and having similar 166 signaling functions. Leveraging the hQR41 reporter assay in HEK293T cells, we over-expressed 167 human or mouse BRSK1, BRSK2 or both. Like BRSK2, BRSK1 expression suppressed NRF2-168 dependent transcriptional activation ( Fig. 2G ). We also performed the hQR41 reporter assay in 169
Keap1 -/-MEFs, which express high levels of NRF2 ( Fig. 2H ). Again, both BRSK1 and BRSK2 170 inhibited NRF2-driven transcription, suggesting that the mechanism of suppression was 171 independent of KEAP1-mediated ubiquitylation. Finally, we evaluated the impact of BRSK1 and 172
BRSK2 on a panel of pathway specific transcriptional reporters in HEK293T cells ( Fig. 2I ). BRSK1 173 and BRSK2 suppressed NRF2 and retinoic acid receptor (RAR) and activated the Activator 174
Protein-1 (AP1), Activating Transcription Factor 3 (ATF3), and Transforming Growth Factor β 175 (TGFβ) reporters. Neither BRSK family member regulated the WNT/β-catenin reporter, NFκB 176 reporter or STAT reporter. As such, BRSK1 and BRSK2 have redundant and conserved functions 177 in NRF2 suppression, and do not impact all signaling pathways equally. 178
Finally, we evaluated the effect of BRSK2 silencing on NRF2 protein expression and NRF2-driven 179 transcription. HEK293T cells were engineered to express dead KRAB-dCas9 nuclease before 180 stable introduction of 4 scrambled control sgRNAs or 5 independent BRSK2-specific sgRNAs. 181
W.blot analysis of the resulting cell lines confirmed efficient sgRNA-mediated CRISPRi silencing 182 of BRSK2 protein and no effect on NRF2 protein levels ( Fig. S1A ). NRF2 hQR41 reporter assays 183 in these cells did not show a BRSK2-silencing phenotype on NRF2 activity. Since BRSK2 RNA 184 levels are highest in brain and pancreas, we evaluated BRSK2 expression in pancreatic cancer 185 cell lines ( Fig. S1C ). Two cell lines, PANC1 and MIA PaCa-2, expressed the most BRSK2, of 186 which we used MIA PaCa-2 for CRISPRi silencing. Like HEK293T cells, MIA PaCa-2 cells 187 deficient for BRSK2 expressed comparable levels of NRF2 as control cells (Fig. S1D ). These data 188
suggest that under homeostatic conditions, endogenous levels of BRSK2 does not control NRF2 189
activity. Further experiments in BRSK2 null background as opposed to silenced background are 190 needed. 191 BRSK2 kinase function is required to suppress NRF2 signaling. 192
We next determined whether BRSK2-mediated inhibition of NRF2 required BRSK2 kinase activity. 193 We mutated K48 and D141 in the kinase domain of BRSK2; these residues are required for ATP 194 binding and substrate phosphorylation (Lizcano et al., 2004) . We also mutated T174, which is 195 phosphorylated by LKB1 to activate members of the AMPK kinase family ( Fig. 3A ) (Lizcano et al., 196 2004) . Compared to controls, over-expression of wild type BRSK2 decreased NRF2-dependent 197 hQR41 luciferase expression whereas kinase dead variants had no significant affect ( Fig. 3B ).
198
The kinase dependency of BRSK2 was further confirmed using qRT-PCR of endogenous NRF2 199 target gene HMOX1, which was repressed by wild type BRSK2, but not by the kinase dead 200 mutants ( Fig. 3C ). qRT-PCR for the NRF2 transcript showed that expression of neither wild type 201 nor kinase dead BRSK2 mutants affected NRF2 mRNA levels ( Fig. 3D ). Finally, we evaluated 202 NRF2 protein levels in HEK293T cells over-expressing BRSK2 or the kinase dead mutants. As 203 expected, NRF2 protein levels were decreased by over-expression of wild type, but not kinase 204 dead BRSK2 ( Fig. 3E ). Similarly, kinase dead mutants of BRSK1 did not impact NRF2 signaling 205 ( Fig. 3F ). of the AIS or KA1 domain results in an active BRSK2 kinase. We created and expressed mutant 214 proteins in HEK293T cells followed by hQR41 reporter quantitation and NRF2 W.blot analysis 215
( Fig. 3G-J) . The L309D and ∆YFLLL mutations within the UBA domain did not suppress the 216 hQR41 reporter and NRF2 or its target genes in W.blot analysis ( Fig.3G and 3H, respectively).
217
Based on previous reports on the role of the BRSK2 UBA domain, it is likely that loss of YFLLL 218 motif increases auto-inhibition by the AIS/KA1 region (Wu et al., 2015). Mutations of UBA residues 219 that contact the kinase domain, M332K and Y334F, repressed NRF2 activity. We next deleted 220 the kinase domain (∆N), C-terminus (∆C), PRR (∆PRR), AIS (∆AIS), or KA1 (∆KA1) domain and 221 evaluated their effect on NRF2-mediated transcription via reporter assays ( Fig. 3I ). Compared to 222 controls, BRSK2 ∆KA1 and ∆AIS inhibited NRF2 activity to similar or more than BRSK2 WT, while 223 loss of either kinase, C-terminal, or PRR regions abolished regulation of NRF2 signaling ( Fig. 3J ). 224
BRSK2 does not repress NRF2 via the ubiquitin proteasome system (UPS). 225
NRF2 is rapidly stabilized by electrophilic compounds that react with cysteines in KEAP1. NRF2 226 protein levels also accumulate within minutes of chemical inactivation of the ubiquitin proteasome 227 system (UPS). We tested whether BRSK2 expression would suppress NRF2 stabilized by KEAP1 228
reactive electrophiles or inhibitors of the UPS. First, we treated HEK293T cells with vehicle, 229
Sulforaphane, or tBHQ for 6 hours after 24 hours of BRSK2 expression. Like CDDO-me, these 230 compounds modify cysteine residues on KEAP1 to stabilize NRF2 (Suzuki et al., 2019). Cells 231 over-expressing BRSK2 significantly downregulated NRF2 protein levels compared to the 232 corresponding control ( Fig. 4A , quantification below). Second, we tested the proteasomal 233 inhibitors MG132 and Bortezomib as well as the CUL3 neddylation inhibitor MLN4924. NRF2 234 protein levels were decreased by BRSK2 in all treatment groups compared to the control, 235 although to varying degrees ( Fig. 4B , quantification below). Lastly, we asked whether BRSK2-236 mediated downregulation of NRF2 involved the autophagy pathway. To evaluate this, we treated 237 BRSK2 overexpressing HEK293T cells with vehicle or Bafilomycin A (BafA1) for 12 hours. 238
Compared to vehicle, BafA1 treatment did not significantly affect NRF2 in either control or BRSK2 239 over-expressing conditions ( Fig. 4C , quantified below). LC3B conversion confirmed efficacy of 240
BafA1 treatment. These data suggest that BRSK2-mediated downregulation of NRF2 is not via 241 the UPS or autophagy. 242
RNAseq and phosphoproteomic characterization BRSK2 and BRSK1 expression. 243
Unbiased comprehensive screening and molecular annotation has improved significantly over the 244 past decade, with newly empowered informatics that distill the resulting large datasets into 245 pathways and biological processes. To better understand BRSK2/1 function in cells, and to 246 possibly reveal how BRSK2 suppresses NRF2, we performed RNAseq and global quantitative 247 phosphoproteomic analysis on HEK293T cells expressing BRSK2 and BRSK1 as compared to 248 mock transfected or hcRED expression. Hierarchical clustering analysis revealed genes altered 249 by BRSK2/1 over-expression, where genes that passed FDR (FDR < 5%) and fold change (FC ≥ 250
2) cutoff are highlighted ( Fig. 5A and B ). Compared to control, we observed 723 and 879 251 differentially expressed genes that pass FDR < 5% for BRSK2 and BRSK1, respectively. Based 252 on fold change, differential gene expression due to BRSK2 expression was more robust than 253 BRSK1. Gene set enrichment analysis (GSEA) using the Hallmark and Oncogenic gene sets in 254
MSigDB revealed statistically significantly altered signaling pathways (Table S5 -S8) . Genes 255 associated with mTOR signaling were robustly downregulated in BRSK2/1 expressing cells ( Fig.  256 5C). GSEA for several NRF2 gene signatures revealed downregulation by BRSK2 ( Fig. S2 , Table  257 S9). Close examination by pathway analysis of the downregulated genes revealed enrichment for 258 those involved in pyruvate, glutathione, and amino acid metabolism. Interestingly, several of the 259 genes are known players in ferroptosis, a non-canonical and iron dependent cell death pathway 260 (Table S9) . 261
Independently of the RNAseq analyses, we performed tandem mass tags (TMT)-based 262 quantitative phosphoproteomics on BRSK2/1 expressing cells where we used hcRED as control.
263
Biological triplicate samples were analyzed, revealing ~10,000 phosphosites in ~8,400 phospho-264 peptides. Following the RNAseq trend, BRSK2 impacted phospho-proteome more robustly than 265 did BRSK1. Compared to control, at FDR < 5%, BRSK2 over-expression induced 307 differentially 266 phosphorylated peptides compared to 189 observed in BRSK1 over-expression (Table S10 ). We 267
leveraged PTMSigDB and enrichment analysis to map the observed phospho-peptide changes 268
to annotated signaling pathways ( Fig. 5D and E) (Krug et al., 2019) . BRSK2/1 positively regulated 269
AMPK and AKT signaling, while negatively impacting the mTOR pathway. BRSK2 also 270 suppressed signaling through the CDK1, CDK2, and CDC7 pathways (Table S12) . 271
To confirm activation of AMPK signaling, BRSK2 was expressed in HEK293T cells before W.blot 272 analysis for phosphorylation of AMPK substrates (LxRxx(pS/pT)). We expressed either wild type 273 Finally, because BRSK2/1 over-expression suppressed mTOR, we quantified the rate of protein 282 translation after BRSK2/1 expression ( Fig. 6C ). HEK293T cells expressing BRSK2/1 or control 283 hcRED were pulsed with 35 S-Methionine before lysis and quantitation of nascent polypeptides, 284
where Cyclohexamide (CHX) served as a negative control. Compared to control and kinase dead 285 BRSK2, expression of wild type BRSK2 and BRSK1 downregulated protein translation by 40% 286 and 10%, respectively ( Fig. 6C ). To further confirm decreased translation, we measured ribosome 287 binding to mRNA in cells expressing BRSK2/1. Cells transfected with the indicated construct were 288 fractionated in a 10% -50% sucrose gradient followed by absorbance measurement for 289 polyribosome tracing. Compared to control and kinase dead BRSK2, over-expression of wild type 290
BRSK2 decreased heavy polyribosome formation on mRNA (Fig. 6D) . 291 292
Discussion 293
The NRF2 transcription factor is central to a growing number of human pathologies. and Non-essential amino acids (Corning, 10-092-CV). 365
Generation of CRISPRi Cell lines 366
Lentivirus for KRAB-dCas9 was generated by using PsPax2 and PMD2G packaging vectors 367 (Gilbert et al., 2014) . HEK293T and MIA PaCa-2 cells were infected with KRAB-dCas9 lentivirus 368
and monoclonal lines were generated via single cell sorting following 10µg/mL Blasticidin (GIBCO, 369 A11139-03) selection for 5 passages. Each monoclonal line was cultured in 5µg/mL Blasticidin 370 following sorting. Single guide RNA (sgRNA) vectors were generated by ligating oligonucleotides 371
into AarI (ThermoFisher Scientific, ER1582) digested VDB783 vector (Table S1 ). Each sgRNA 372
was lentivirally introduced to the above mentioned cell lines, and cells were cultured for 3 373 passages in 2.5µg/mL Puromycine (Corning, 61-385-RA) and 5µg/mL Blasticidin before further 374
analysis. Stable cell lines were maintained in 1µg/mL Puromycine and 5µg/mL Blasticidin. 375
Plasmids and Reagents 376
The human kinome ORF library in pDONOR223 was obtained from Addgene ( Table S2 . 420
qRT-PCR and RNA sequencing analysis 421
RNA was collected using PureLink RNA Mini Kit (Invitrogen, 12183018A) per manufacturer 422
instruction. The extracted RNA was then reverse transcribed to cDNA using iScript cDNA 423
Synthesis Kit (BioRad, 170-8891), which was then used to perform quantitative RT-PCR (qRT-424 PCR) using SYBR Green (Applied Biosystems, 4385617) for the specified target genes ( Table  425 S3). 426 3µg of RNA was submitted to Novogene Corp. Ltd. (Sacramento, CA) for sequencing using 427
Illumina HiSeq platform where reads were mapped to reference genome Homo sapiens 428 (GRCh37/hg19). Alignments were done using STAR/HTSeq. Differential expression analysis was 429 performed starting with gene level read count quantification provided by Novogene Corp. 430
Preprocessing, normalization, and differential expression analysis were performed according to Gene set enrichment analysis (GSEA) was performed based on the above described pre-438
processed read counts which were converted to counts per million and log2 transformed 439 (logCPM). From 13,000 genes the top 10,000 differentially expressed genes were used for GSEA 440 analysis. Genes were ranked according to signal to noise ratio as defined by the Broad Institute 441
GSEA software using the R-project fgsea package. 
Translation assay and polysome fractionation 446
Rate of protein translation was measured in HEK293T cells expressing controls or BRSK2/1 24 447 hours post transfection using radioactive methionine ( 35 S-Met) labeling, and polysome 448 fractionation was performed as previously described (Graves et al., 2019; Lenarcic et al., 2014) . 449
Phosphoproteomics sample processing and data analysis 450
Protein from HEK293Ts expressing control or BRSK2/1 (1.4mg) was precipitated in acetone 451
overnight at -20°C. The sample was pelleted and re-suspended in 7M urea, reduced with 5mM 452 DTT (dithiothreitol) and alkylated with 15mM CAA (chloroacetamide were analyzed in the Orbitrap at a resolution of 120,000 and 4e5 AGC target. The MS2 spectra 485
were collected using a 0.7 m/z isolation width and analyzed by the linear ion trap using 1e4 AGC 486 target after HCD fragmentation at 30% collision energy with 50ms maximum injection Acknowledgements 500
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